Enteric dysbiosis in liver and kidney transplant recipients: a systematic review
- PMID: 32640109
- DOI: 10.1111/tri.13696
Enteric dysbiosis in liver and kidney transplant recipients: a systematic review
Abstract
Several factors mediate intestinal microbiome (IM) alterations in transplant recipients, including immunosuppressive (IS) and antimicrobial drugs. Studies on the structure and function of the IM in the post-transplant scenario and its role in the development of metabolic abnormalities, infection, and cancer are limited. We conducted a systematic review to study the taxonomic changes in liver (LT) and kidney (KT) transplantation, and their potential contribution to post-transplant complications. The review also includes pre-transplant taxa, which may play a critical role in microbial alterations post-transplant. Two reviewers independently screened articles, and assessed risk of bias. The review identified 13 clinical studies, which focused on adult kidney and liver transplant recipients. Patient characteristics and methodologies varied widely between studies. Ten studies reported increased an abundance of opportunistic pathogens (Enterobacteriaceae, Enterococcaceae, Fusobacteriaceae, and Streptococcaceae) followed by butyrate-producing bacteria (Lachnospiraceae and Ruminococcaceae) in nine studies in post-transplant conditions. The current evidence is mostly based on observational data and studies with no proof of causality. Therefore, further studies exploring the bacterial gene functions rather than taxonomic changes alone are in demand to better understand the potential contribution of the IM in post-transplant complications.
Keywords: immunosuppression; intestinal microbiome; kidney transplantation; liver transplantation; opportunistic pathogens; post-transplant complications.
© 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
References
-
- Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transplant 2013; 19: 3.
-
- Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010; 21: 852.
-
- Siddiqui MS, Sterling RK. Posttransplant metabolic syndrome. Int J Hepatol 2012. https://doi.org/10.1155/012/891516.
-
- Jiménez-Pérez M, González-Grande R, Guzmán EO, Trillo VA, López JMR. Metabolic complications in liver transplant recipients. World J Gastroenterol 2016; 2: 6416.
-
- Rahim HP, Taylor MR, Hirota SA, Greenway SC. Microbiome alterations following solid-organ transplantation: consequences, solutions, and prevention. Transplant Res Risk Manage 2018; 10: 1.